Overview

Mucomyst for Hepatitis C

Status:
Suspended
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The study will examine the effects of treatment with N-acetylcysteine ( Mucomyst ) 1 gm twice a day for 30 dyas in 15 patients with hepatitis C. The primary outcome of interest wil be the changes in oxidant stress as measured by different oxidant stress markers level in sera. Secondary outcomes of interest will be changes in viral load of hep C and changes in liver function
Phase:
N/A
Details
Lead Sponsor:
US Department of Veterans Affairs
VA Office of Research and Development
Collaborator:
West Virginia University
Treatments:
Acetylcysteine
N-monoacetylcystine